Amantanium bromide NEW
Price | $297 | $696 | $942 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Amantanium bromide | CAS No.: 58158-77-3 |
Purity: 99.97% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Amantanium bromide |
Description | Amantanium bromide (Amantanil bromidum) is a quaternary ammonium antibacterial/antifugal agent useful as a surgical antiseptic and for the topical therapy of mucous and cutaneous infections. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 60 mg/ml (126.97 mM) |
Keywords | inhibit | Amantanium bromide | Amantanium | Inhibitor | Amantanium Bromide |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/25kg |
VIP1Y
|
Taicang Puyuan Pharmaceutical Co., Ltd.
|
2025-01-02 | |
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-10-09 | |
$297.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY